Navigation Links
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Date:4/8/2009

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Presidential Symposium at the Annual European Bone Marrow Transplantation meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6 highest ranked presentations, representing the most promising new developments in the transplantation field, were selected for this Symposium.

ATIR(TM), a donor lymphocyte cell based preparation depleted of allo-reactive T-cells, is under development to prevent acute Graft versus Host Disease (GvHD) and allow for early immune reconstitution following a bone marrow transplantation with a fully mismatched (haplo-identical) donor.

Dr. Roy's presentation of clinical results from 19 end stage blood cancer patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well received. These patients, each of whom did not have a matched donor available, were treated in a phase I/II dose escalating study with ATIR(TM) in a mismatched transplantation setting. No immune suppressants were used, which is in contrast to conventional transplant procedures. Nevertheless, no cases of severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a reduction in the frequency of infectious episodes in the cohorts treated with the higher doses of ATIR(TM), as compared to the low dose cohorts. To date, patients in the higher dose cohorts show high survival rates (75%) with no transplant related mortality (TRM).

These results show that the selective depletion of allo-reactive T-cells in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent TH9402 is highly effective and can result in fast and adequate immune reconstitution in combination with the prevention of acute GvHD in bone marrow transplantations using a mismatched donor.

Dr. Denis-Claude Roy, Head of Stem Cell Therapy of the Hospital Maisonneuve-Rosemont, Montreal, Canada says: "These are fascinating results, demonstrating the feasibility of performing mismatched transplantations with an ATIR(TM) infusion. These results may give hope to patients who currently cannot be treated because of limited donor availability. In the future ATIR(TM) may allow mismatched transplantations to be performed in virtually all patients who cannot find a donor thereby improving the outcome of the whole procedure."

Dr. Manja Bouman, CEO of Kiadis Pharma, says: "Kiadis Pharma is pleased with the election of our ATIR(TM) data to be presented at the Presidential Symposium of the EBMT. It shows the interest in our approach by the medical community. On the basis of these highly encouraging results we are currently preparing for a multinational registration study with ATIR(TM) in mismatched transplantation procedures."

Go to http://www.kiadis.com for the complete press release


'/>"/>
SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
2. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
5. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
6. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
7. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
8. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
9. New Pharmaxis Board Appointment
10. Pharmaxis Investor Conference Call
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):